A study of JNJ-80038114 in participants with advanced stage prostate cancer
- Conditions
- CancerProstate cancer
- Registration Number
- ISRCTN16457874
- Lead Sponsor
- Janssen-Cilag International NV
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- Male
- Target Recruitment
- 49
1. 18 years and older
2. Metastatic castration-resistant prostate cancer (mCRPC) with confirmed adenocarcinoma of the prostate as defined by Prostate Cancer Working Group 3 (PCWG3)
3. Measurable or evaluable disease
4. At least 1 prior treatment for mCRPC
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
6. Adequate organ functions as defined by certain laboratory values
7. Must sign an informed consent form (ICF)
8. Participants must agree to use a highly effective form of birth control as guided by the study doctor
1. Concurrent anticancer therapy
2. Severe or long-lasting side effects related to prior anticancer therapy
3. Known allergies to JNJ-80038114 or its excipients
4. Brain metastasis or known seizure history
5. Significant infections or lung, heart or other medical conditions
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method